Mixed
Sarcopenic obesity, defined as the concurrent presence of low muscle mass and high adiposity, has a compounding negative impact on health outcomes and is common in chronic disease populations.
For obese patients, especially those with chronic diseases, focusing solely on weight loss may be counterproductive. It is crucial to assess and preserve muscle mass through targeted interventions like resistance training and adequate protein intake, as sarcopenic obesity is associated with worse outcomes than obesity alone.
The concurrent appearance of low muscle mass with high adiposity (also termed sarcopenic obesity) is the new face of an old problem, common in people who face chronic diseases. This condition has a compounding impact on health and outcomes.
Why this rating
Supported by multiple studies across different disease states (heart failure, COPD, cancer) showing worse outcomes in sarcopenic obesity.
Source
Implications of low muscle mass across the continuum of care: a narrative review
Carla M. Prado et al. · Annals of Medicine · 2018
DOI 10.1080/07853890.2018.1511918
More from this paper
- Low muscle mass is a significant predictor of poor clinical outcomes, including higher surgical complications, longer hospital stays, reduced physical function, and shorter survival, across diverse patient populations in inpatient, outpatient, and long-term care settings.Good
- Muscle quality, assessed by muscle attenuation (fat infiltration) via CT or MRI, is an independent and emerging prognostic indicator for survival and outcomes, often more predictive than muscle mass alone.Good
Related findings · Mixed
- Bariatric surgery (VSG and RYGB) is the most effective and sustainable treatment for obesity, producing marked and sustained weight loss that non-surgical interventions cannot match.Strong
- Severely protein-deficient diets (2–3% energy) induce lean body mass loss and metabolic imbalance, whereas adequate protein intake (0.66 g/kg/d minimum) is a prerequisite for maintaining muscle, bone, and physiological function.Strong
- For patients with Class III obesity (BMI >39.9 kg/m2), metabolic bariatric surgery (MBS) is significantly more effective than any currently approved medication, with BilioPancreatic Diversion (BPD) showing the highest estimated weight loss.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →